Longevity medicine relies on advanced biomarker analysis to support preventive healthcare and more personalized patient ...
Finerenone shows promise in slowing chronic kidney disease progression in non-diabetic patients, according to recent global ...
The U.S. Food and Drug Administration has approved Vera Therapeutics' drug to treat patients with a potentially ...
TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA ...
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...
A surprising finding has revealed that the kidneys may control water retention through an additional pathway beyond the one ...
ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patientsFirst-in-human SAD study in healthy volunteers ...
Noticing your socks leave deep marks around your ankles at the end of the day can easily be shrugged off. It is incredibly ...
A 26-year-old’s vitamin D habit led to kidney failure and dialysis. Here is why you should never skip the blood test before ...
Vera Therapeutics’ atacicept, to be marketed as Trutakna, will go up against Novartis, Otsuka and possibly Vertex in the kidney disease primary IgA nephropathy after receiving an accelerated FDA ...
The phase 2 BESTOW trial is testing calcineurin inhibitor-free maintenance therapy with tegoprubart vs tacrolimus in kidney transplant recipients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results